Decrease in expression or activity of cytosolic phospholipase A2α increases cyclooxygenase-1 action: A cross-talk between key enzymes in arachidonic acid pathway in prostate cancer cells

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1801, Issue 7, 2010, Pages 731-737

  Niknami, Marzieh ^a   Vignarajan, Soma ^a   Yao, Mu ^a   Hua, Sheng ^a   Witting, Paul K ^b   Kita, Yoshihiro ^c   Shimizu, Takao ^c   Sved, Paul ^b   Patel, Manish I ^b   Dong, Qihan ^a  

^a SYDNEY CANCER CENTRE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

cPLA2 ; Cyclooxygenase; Lipoxygenase; Prostate cancer

Indexed keywords

ARACHIDONIC ACID; CYCLOOXYGENASE 1; EFIPLADIB; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; NEGATIVE FEEDBACK; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY;

12-HYDROXY-5,8,10,14-EICOSATETRAENOIC ACID; ARACHIDONIC ACID; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DINOPROSTONE; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GROUP IV PHOSPHOLIPASES A2; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; MALE; NEOPLASM PROTEINS; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; TRANSCRIPTION, GENETIC;

EID: 77952550668     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2010.03.003     Document Type: Article

References (29)

1. Dannenberg A.J., Altorki N.K., Boyle J.O., Dang C., Howe L.R., Weksler B.B., and Subbaramaiah K. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol. 2 (2001) 544-551
2. Harris R.E., Beebe-Donk J., Doss H., Burr Doss D., Harris R.E., Beebe-Donk J., Doss H., and Burr Doss D. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol. Rep. 13 (2005) 559-583
3. Pruthi R.S., Derksen J.E., Moore D., Carson C.C., Grigson G., Watkins C., and Wallen E. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Clin. Cancer Res. 12 (2006) 2172-2177
4. Smith M.R., Manola J., Kaufman D.S., Oh W.K., Bubley G.J., and Kantoff P.W. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J. Clin. Oncol. 24 (2006) 2723-2728
5. Anderson K.M., Seed T., Vos M., Mulshine J., Meng J., Alrefai W., Ou D., and Harris J.E. 5-Lipoxygenase inhibitors reduce PC-3 cell proliferation and initiate nonnecrotic cell death. Prostate 37 (1998) 161-173
6. Fujishima H., Sanchez Mejia R.O., Bingham III C.O., Lam B.K., Sapirstein A., Bonventre J.V., Austen K.F., and Arm J.P. Cytosolic phospholipase A2 is essential for both the immediate and the delayed phases of eicosanoid generation in mouse bone marrow-derived mast cells. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 4803-4807
7. Garraway L.A., Lin D., Signoretti S., Waltregny D., Dilks J., Bhattacharya N., and Loda M. Intermediate basal cells of the prostate: in vitro and in vivo characterization. Prostate 55 (2003) 206-218
8. Patel M.I., Singh J., Niknami M., Kurek C., Yao M., Lu S., Maclean F., King N.J., Gelb M.H., Scott K.F., Russell P.J., Boulas J., Dong Q., Patel M.I., Singh J., Niknami M., Kurek C., Yao M., Lu S., Maclean F., King N.J.C., Gelb M.H., Scott K.F., Russell P.J., Boulas J., and Dong Q. Cytosolic phospholipase A2-alpha: a potential therapeutic target for prostate cancer. Clin. Cancer Res. 14 (2008) 8070-8079
9. Cummings B.S. Phospholipase A2 as targets for anti-cancer drugs. Biochem. Pharmacol. 74 (2007) 949-959
10. Dong Q., Patel M., Scott K.F., Graham G.G., Russell P.J., and Sved P. Oncogenic action of phospholipase A2 in prostate cancer. Cancer Lett. 240 (2006) 9-16
11. Axelrad T.W., Deo D.D., Ottino P., Van Kirk J., Bazan N.G., Bazan H.E., and Hunt J.D. Platelet-activating factor (PAF) induces activation of matrix metalloproteinase 2 activity and vascular endothelial cell invasion and migration. FASEB J. 18 3 (2004) 568-570
12. Bussolati B., Biancone L., Cassoni P., Russo S., Rola-Pleszczynski M., Montrucchio G., and Camussi G. PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angiogenesis. Am. J. Pathol. 157 5 (2000) 1713-1725
13. Seo K.H., Lee H.S., Jung B., Ko H.M., Choi J.H., Park S.J., Choi I.H., Lee H.K., and Im S.Y. Estrogen enhances angiogenesis through a pathway involving platelet-activating factor-mediated nuclear factor-kappaB activation. Cancer Res. 64 (2004) 6482-6488
14. Bellezza I., Bracarda S., Caserta C., and Minelli A. Targeting of EGFR tyrosine kinase by ZD1839 ("Iressa") in androgen-responsive prostate cancer in vitro. Molec. Genet. Metab. 88 (2006) 114-122
15. Kita Y., Takahashi T., Uozumi N., Shimizu T., Kita Y., Takahashi T., Uozumi N., and Shimizu T. A multiplex quantitation method for eicosanoids and platelet-activating factor using column-switching reversed-phase liquid chromatography-tandem mass spectrometry. Anal. Biochem. 342 (2005) 134-143
16. DeLong C.J., and Smith W.L. An intronic enhancer regulates cyclooxygenase-1 gene expression. Biochem. Biophys. Res. Commun. 338 (2005) 53-61
17. Inoue H., Yokoyama C., Hara S., Tone Y., and Tanabe T. Transcriptional regulation of human prostaglandin-endoperoxide synthase-2 gene by lipopolysaccharide and phorbol ester in vascular endothelial cells. Involvement of both nuclear factor for interleukin-6 expression site and cAMP response element. J. Biol. Chem. 270 (1995) 24965-24971
18. Patel M.I., Tuckerman R., and Dong Q. A Pitfall of the 3-(4, 5-dimethylthiazol-2-yl)-5(3-carboxymethonyphenol)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay due to evaporation in wells on the edge of a 96 well plate. Biotechnol. Lett. 27 (2005) 805-808
19. Ni Z., Okeley N.M., Smart B.P., and Gelb M.H. Intracellular actions of group IIA secreted phospholipase A2 and group IVA cytosolic phospholipase A2 contribute to arachidonic acid release and prostaglandin production in rat gastric mucosal cells and transfected human embryonic kidney cells. J. Biol. Chem. 281 (2006) 16245-16255
20. Lee P.P., and Ip M.M. Regulation of proliferation of rat mammary tumor cells by inhibitors of cyclooxygenase and lipoxygenase. Prostaglandins Leukot. Essent. Fat. Acids 45 1 (1992) 21-31
21. Cianchi F., Cortesini C., Magnelli L., Fanti E., Papucci L., Schiavone N., Messerini L., Vannacci A., Capaccioli S., Perna F., Lulli M., Fabbroni V., Perigli G., Bechi P., Masini E., Cianchi F., Cortesini C., Magnelli L., Fanti E., Papucci L., Schiavone N., Messerini L., Vannacci A., Capaccioli S., Perna F., Lulli M., Fabbroni V., Perigli G., Bechi P., and Masini E. Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells. Mol. Cancer Ther. 5 (2006) 2716-2726
22. Patel M.I., Kurek C., Dong Q., Patel M.I., Kurek C., and Dong Q. The arachidonic acid pathway and its role in prostate cancer development and progression. J. Urol. 179 (2008) 1668-1675
23. McKew J.C., Lee K.L., Shen M.W., Thakker P., Foley M.A., Behnke M.L., Hu B., Sum F.W., Tam S., Hu Y., Chen L., Kirincich S.J., Michalak R., Thomason J., Ipek M., Wu K., Wooder L., Ramarao M.K., Murphy E.A., Goodwin D.G., Albert L., Xu X., Donahue F., Ku M.S., Keith J., Nickerson-Nutter C.L., Abraham W.M., Williams C., Hegen M., Clark J.D., McKew J.C., Lee K.L., Shen M.W.H., Thakker P., Foley M.A., Behnke M.L., Hu B., Sum F.-W., Tam S., Hu Y., Chen L., Kirincich S.J., Michalak R., Thomason J., Ipek M., Wu K., Wooder L., Ramarao M.K., Murphy E.A., Goodwin D.G., Albert L., Xu X., Donahue F., Ku M.S., Keith J., Nickerson-Nutter C.L., Abraham W.M., Williams C., Hegen M., and Clark J.D. Indole cytosolic phospholipase A2 alpha inhibitors: discovery and in vitro and in vivo characterization of 4-{3-[5-chloro-2-(2-{[(3, 4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propyl}benzoic acid, efipladib. J. Med. Chem. 51 (2008) 3388-3413
24. Lin W.W., and Chen B.C. Induction of cyclo-oxygenase-2 expression by methyl arachidonyl fluorophosphonate in murine J774 macrophages: roles of protein kinase C, ERKs and p38 MAPK. Br. J. Pharmacol. 126 (1999) 1419-1425
25. Smith W.L., DeWitt D.L., and Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 69 (2000) 145-182
26. Taniura S., Kamitani H., Watanabe T., Eling T.E., Taniura S., Kamitani H., Watanabe T., and Eling T.E. Transcriptional regulation of cyclooxygenase-1 by histone deacetylase inhibitors in normal human astrocyte cells. J. Biol. Chem. 277 (2002) 16823-16830
27. Chakraborty I., Das S.K., Wang J., and Dey S.K. Developmental expression of the cyclo-oxygenase-1 and cyclo-oxygenase-2 genes in the peri-implantation mouse uterus and their differential regulation by the blastocyst and ovarian steroids. J. Mol. Endocrinol. 16 (1996) 107-122
28. Daikoku T., Wang D., Tranguch S., Morrow J.D., Orsulic S., DuBois R.N., and Dey S.K. Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. Cancer Res. 65 (2005) 3735-3744
29. Daikoku T., Tranguch S., Trofimova I.N., Dinulescu D.M., Jacks T., Nikitin A.Y., Connolly D.C., Dey S.K., Daikoku T., Tranguch S., Trofimova I.N., Dinulescu D.M., Jacks T., Nikitin A.Y., Connolly D.C., and Dey S.K. Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer. Cancer Res. 66 (2006) 2527-2531